Rezolute (RZLT) released an investor presentation providing a comprehensive update on its late-stage clinical programs for its lead candidate, ersodetug, for treating refractory hypoglycemia. The company highlighted positive regulatory feedback from the FDA regarding a path forward for its congenital hyperinsulinism program and confirmed the timeline for a key data readout for its tumor hyperinsulinism study.
Key Details
- Congenital Hyperinsulinism (HI) Update: Following a review of additional data from the Phase 3 sunRIZE study, the FDA has encouraged Rezolute to request a pre-BLA (Biologics License Application) meeting, signaling a potential regulatory path forward despite the study not meeting its primary endpoint.
- Tumor Hyperinsulinism (HI) Milestone: The company expects to report topline data from its Phase 3 upLIFT registrational study in mid-December 2026. Interim results showed 7 of the initial 8 participants met the study's primary endpoint.
- Financial Position & Market: Rezolute reported a cash position of $108 million, providing a projected cash runway through Q1 2028. The company estimates a combined U.S. market opportunity of over $5 billion for ersodetug across congenital and tumor HI indications.